

Tori Terrell Hall, Ph.D.

Levelland, Texas
thall@southplainscollege.edu

EDUCATION

INSTITUTION

West Virginia University
School of Pharmacy,
Department of Pharmaceutical
Sciences
Morgantown, WV 26506

DEGREE

Ph.D., Pharmaceutical and
Pharmacological Sciences

YEAR

2016

Dissertation Title: *Distribution and efficacy of
chemotherapeutics in the treatment of preclinical
brain metastases of breast cancer.*

West Texas A&M University
Canyon, TX 79015

B.S.
Biology & Chemistry

2011

PROFESSIONAL EXPERIENCE

Instructor of Biology: BIOL 2420: Microbiology

August 2020 – Current

South Plains College, Levelland, TX

- Course administrator and sole instructor.
- Fall, spring, and summer course. Instruct students planning a career in the allied health sciences on major microbiological concepts.
- Solely responsible for developing and writing lectures and labs for 1 – 2 sections (4 - 8 ACH) of Microbiology. Course includes 25 lectures and 13 foundational labs with an 8 week unknown bacteria research project.
- This course covers foundations of microbiology with an emphasis on microbial relationships to disease, pathogenicity, and the immune response. The main objectives of the lecture are to introduce microbiological principles, understanding of microbial morphology and physiology, bacteria genetics, and basic disease processes, and to incorporate a lab that allows hands on investigation of the topics covered in lecture.
- Delivery methods taught: Face-to-face, flex (or hybrid), and fully online.
- Format: Lecture-based, laboratory-based, and problem-based.
- Undergraduate. Average class size: 36.

Adjunct Professor of Biology: BIOL 2420: Microbiology

August 2018 – August 2020

South Plains College, Levelland, TX

- See “Instructor of Biology” description above.

Science Content Developer – Independent Contractor

November 2017 – Current (~ 1 project per year)

GEX Publishing Services, Inc.

- I work on a variety of projects with GEX (as needed) that range from microbiology, to chemistry, to biochemistry. I create and develop, review, and revise instructional texts, learning objectives, assessment questions, tests, and supplementary material.

Independent Consultant

August 2017 – December 2018

Independent Consultant for CFDRC

- Provided a comprehensive list of all equipment needed and on site set up for any academic or industry lab interested in using CFDRC's devices. Provided a 3-5 day comprehensive on-site training of the desired microfluidic devices: How the devices work; How to successfully and accurately utilize the devices; and real-time seeding of the device, maturity of the cells in the device, and the running of an experiment. Was the point of contact between CFDRC and the academic labs regarding troubleshooting the devices for a set period of time.

Laboratory Manager, Mentor, Research Assistant

July 2013 – December 2016

Paul Lockman, West Virginia University

- Established and maintained relationships with undergraduate, graduate, and professional students, as well as various faculty, staff, and university leadership to establish and collaborate with the Dr. Paul Lockman's lab.
- Established and maintained relationships with the CFD Research Corporation for the validation of a novel *in-vitro* microfluidic device, and played a lead role in the bioengineering of multiple other novel *in-vitro* microfluidic devices.
- Attended national, regional, and local scientific conferences: educated scientists, students, physicians on the disease state and treatment of preclinical brain metastases of breast cancer, analyzed scientific presentations and posters, and prepared summaries of key findings.
- Participated and presented in weekly seminars and journal clubs.
- Organized, mentored, and lead in the scientific training of each incoming student and technician.

COMMUNITY INVOLVEMENT AND SERVICE

Board Member

Family Coaching (nonprofit)

June 2020 – present

PROFESSIONAL PUBLICATIONS – PEER REVIEWED

Terrell-Hall TB, Nounou MI, El-Amrawy F, Griffith JIG, and Lockman PR. (2017) Trastuzumab distribution in an *in-vivo* and *in-vitro* model of brain metastases of breast cancer. *Oncotarget*. eCollection

Terrell-Hall TB, Ammer AG, Griffith JIG, and Lockman PR. (2017) Permeability Across a Novel Microfluidic Blood-Tumor Barrier Model. *Fluids Barriers CNS*. 14;1:3

Venishetty VK, Geldenhuys, WJ, **Terrell-Hall TB**, Griffith JIG, Sodag GR, Safadi FF, and Lockman PR. (2016) Identification of novel agents for the treatment of brain metastases of breast cancer. *Current Cancer Drug Targets*. *EPUB*

Bohn KA, Adkins, CE, Mittapalli RK, **Terrell-Hall TB**, Mohammad AS, Shah N, Dolan EL, Nounou MI, Lockman PR. (2016) Semi-automated rapid quantification of brain vessel density utilizing fluorescent microscopy. *J Neurosci Methods*. 1;270:124-31

Nounou MI, Adkins CE, Rubinchik E, **Terrell-Hall TB**, Afroz M, Vitalis T, Gabathuler R, Tian MM, Lockman PR. (2016) Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study. *Pharm Res.* 33(12):2930-2942

Adkins CE, Mohammad AS, **Terrell-Hall TB**, Dolan EL, Shah N, Sechrest E, Griffith J, Lockman PR. (2016) Characterization of passive permeability at the blood-tumor barrier in five preclinical models of brain metastases of breast cancer. *Clin Exp Metastasis.* 33(4):373-83.

Adkins CE, Nounou MI, Hye T, Mohammad AS, **Terrell-Hall T**, Mohan NK, Eldon MA, Hoch U, Lockman PR. (2015) NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer. *BMC Cancer.* 15:685

Adkins CE, Nounou MI, Mittapalli RK, **Terrell-Hall TB**, Mohammad AS, Jagannathan R, Lockman PR. (2015) A novel preclinical method to quantitatively evaluate early-stage metastatic events at the murine blood-brain barrier. *Cancer Prev Res.* 8(1):68-76.

El-Habashy SE, Nazief AM, Adkins CE, Wen MM, El-Kamel AH, Hamdan AM, Hanafy AS, **Terrell TO**, Mohammad AS, Lockman PR, Nounou MI. (2014) Novel treatment strategies for brain tumors and metastases. *Pharm Pat Anal.* 3(3):279-96.

Adkins CE, Mittapalli RK, Manda VK, Nounou MI, Mohammad AS, **Terrell TB**, Celik Y, Groethe TR, Lockman JA, Lockman PR. (2013) P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model. *Frontiers in Pharmacology.* 4:136.

Mittapalli RK, Liu X, Adkins CE, Nounou MI, Bohn KA, **Terrell TB**, Qhattal HS, Geldenhuys WJ, Palmieri D, Steeg PS, Smith QR, Lockman PR. (2013) Paclitaxel-hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model *Mol Canc Ther.* 12(11): 2389-99; PMID: 24002934

BOOK CHAPTERS

Nounou MI, Adkins CE, **Terrell TB**, Bohn KA, Lockman PR. 2012. Drug Delivery to the CNS: Breaking Down the Barrier. In Book "Drug Delivery" (Edited by. AK Mitra) Jones and Bartlet Learning, Burlington MA. ISBN - 10: 1284025683, ISBN-13: 978-1284025682, 2014.

PRESENTATIONS

Griffith J, **Terrell-Hall T**, Ammer A, Lockman PR. Characterization of a novel microfluidic in vitro model of the blood-tumor and blood-brain barrier. Annual Meeting of the American Association for Cancer Research, Washington DC. April 2017.

Mohammad AS, Adkins CE, **Terrell-Hall TB**, Sechrest ER, Dolan EL, Griffith J, Shah N, Jagannathan R, Lockman PR. "Demonstration of casual relationship between blood-tumor barrier permeability changes and chemotherapeutic uptake and effect in brain micro-metastases of breast cancer". Annual Meeting of the American Association for Cancer Research, New Orleans, LA. April 2016. (Abstract #2080)

Bohn KA, Sechrest E, Adkins CE, Mittapalli RK, Nounou MI, **Terrell-Hall TB**, Mohammad AS, Lockman PR. Inhibition of VEGF and angiopoietin-2 to reduce brain metastases of breast cancer burden. Annual Meeting of American Cancer Society, Philadelphia, PA, 2015

Mohammad AS, Adkins CE, Mittapalli RK, **Terrell-Hall TB**, Nounou MI, Lockman PR. "Characterization of changes in passive permeability and drug uptake at the blood-tumor barrier in four preclinical models of brain metastases of breast cancer." AACR Annual Meeting. Philadelphia, PA. 2015.

Adkins CE, Mittapalli RK, Nounou MI, **Terrell-Hall TB**, Mohammad AS, Lockman PR. Characterization of changes in passive permeability and drug uptake at the blood-tumor barrier in four preclinical models of brain metastases of breast cancer. Annual Meeting of American Cancer Society, Philadelphia, PA, 2015

Bohn KA, Adkins CE, Mittapalli RK, Nounou MI, **Terrell-Hall TB**, Mohammad AS, Lockman PR. Vascular remodeling is associated with increased permeability of experimental brain metastases of breast cancer. Annual Meeting of American Cancer Society, Philadelphia, PA, 2015

Nounou MI, Adkins CE, **Terrell TO**, Mohamed A, Vitalis T, Gabathuler R, and Lockman PR. "Anti-cancer antibody trastuzumab-melanotransferrin conjugate (BT2111) for the treatment of metastatic HER2+ breast cancer tumors in the brain: An in vivo study"; Poster Presentation, The American Association of Cancer Research (AACR) annual meeting, San Diego, CA, USA, April 5-9, 2014.

Nounou MI, Hoch U, Adkins CE, **Terrell TO**, Villalba H, Eldon ME, and Lockman PR. "Etirinotecan pegol accumulates in breast cancer brain metastases and prolongs survival in an experimental model of brain metastases of human triple negative breast cancer"; Poster Presentation, The American Association of Cancer Research (AACR) annual meeting, San Diego, CA, USA, April 5-9, 2014.

Nounou MI, Adkins CE, **Terrell TB**, Villalba H, and Lockman PR; "Characterization of changes in passive permeability and drug uptake at the blood-tumor barrier in four preclinical models of brain metastases of breast cancer"; Poster Presentation, The American Association of Pharmaceutical Scientists (AAPS) annual meeting, San Antonio, TX, USA, November 10-14, 2013.

Hoch U, Nounou MI, Adkins CE, **Terrell TB**, Villalba H, Eldon ME, Perez E, and Lockman PR; "Etirinotecan pegol prolongs survival in an experimental model of brain metastasis of human triple negative breast cancer"; Poster Presentation, European Cancer Congress 2013 (ECCO-ESMO-ESTRO), Amsterdam, Netherlands, September 27th-October 1st 2013.

Gabathuler R, Vitalis TZ, Nounou MI, Iqbal U, Moreno M, Adkins CE, **Terrell TO**, Smith QR, Jefferies WA, and Lockman PR; " BT2111, a New Anti-Cancer Agent composed of Trastuzumab and Transcend a Vector for Brain Delivery for the Treatment of Metastatic Her2+ Breast Cancer"; Poster Presentation, AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, USA, October 19-23, 2013.

Hoch U, Nounou M, Adkins CE, **Terrell TB**, Villalba H, Eldon E, Lockman PR. "Etirinotecan pegol prolongs survival in an experimental model of brain metastasis of human triple negative breast cancer". 17th ECCO – 38th ESMO, Amsterdam, Netherlands. 2013.

Nounou MI, Bohn KA, Adkins CE, **Terrell TB**, Bansal A, Smith QR, Lockman PR. "Effect of Bevacizumab on vascular permeability and drug uptake in brain metastases of breast cancer". Annual Meeting of the American Association of Pharmaceutical Scientists, Chicago, IL 2012.